Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations
- PMID: 9266968
- DOI: 10.1038/sj.onc.1201242
Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations
Abstract
To assess the effect(s) of the C-terminal domain on FGFR2 function, we engineered a series of mutant FGFR2 cDNAs encoding deletions in the C-terminus of the receptor and compared their growth properties in NIH3T3 fibroblasts. In contrast to FGFR2-WT, receptors with C-terminal truncations induced ligand-independent transformation of NIH3T3 cells and transfectants expressing these mutant receptors efficiently formed colonies in semisolid medium. Introduction of point mutations (Y to F) into the C-terminus of FGFR2 at positions 813, 784 or 780 revealed that these mutant receptors also displayed activities similar to that of C-terminally truncated receptors. C-terminally altered FGF receptors did not show an increase in the basal level of receptor phosphorylation compared to that of FGFR2-WT suggesting that elevated receptor phosphorylation does not underlie the transforming activity of these receptors. Interestingly, expression of transforming FGFR2 derivatives, unlike H-Ras transformed cells, did not result in the activation of the mitogen-activated protein kinases (MAPKs), p42/ERK2 and p44/ERK1, indicating that this pathway is not constitutively active in FGFR2-transformed cells. Finally, we report the overexpression of FGFR2 mRNA and protein in several human tumor cell lines suggesting activation of the receptor in these tumors.
Similar articles
-
Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells.Mol Cancer Res. 2004 Nov;2(11):643-52. Mol Cancer Res. 2004. PMID: 15561780
-
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.Oncogene. 2000 Jul 6;19(29):3309-20. doi: 10.1038/sj.onc.1203650. Oncogene. 2000. PMID: 10918587
-
Ligand-independent activation of tyrosine kinase in fibroblast growth factor receptor 1 by fusion with beta-galactosidase.Oncogene. 1995 Jun 15;10(12):2315-22. Oncogene. 1995. PMID: 7784079
-
Trophic signaling pathways activated by purinergic receptors in rat and human astroglia.Prog Brain Res. 1999;120:323-32. doi: 10.1016/s0079-6123(08)63566-9. Prog Brain Res. 1999. PMID: 10551008 Review. No abstract available.
-
Tyrosine kinase signalling in breast cancer.Breast Cancer Res. 2000;2(3):154-7. doi: 10.1186/bcr48. Epub 2000 Apr 17. Breast Cancer Res. 2000. PMID: 11250704 Free PMC article. Review.
Cited by
-
The acidic domain and first immunoglobulin-like loop of fibroblast growth factor receptor 2 modulate downstream signaling through glycosaminoglycan modification.Mol Cell Biol. 1999 Oct;19(10):6754-64. doi: 10.1128/MCB.19.10.6754. Mol Cell Biol. 1999. PMID: 10490614 Free PMC article.
-
Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors.Cell Rep. 2019 Aug 27;28(9):2331-2344.e8. doi: 10.1016/j.celrep.2019.07.021. Cell Rep. 2019. PMID: 31461650 Free PMC article.
-
Case report: High-grade serous tubo-ovarian carcinoma with FGFR2::IQCG fusion and insights into targetability.Front Oncol. 2024 Dec 20;14:1514471. doi: 10.3389/fonc.2024.1514471. eCollection 2024. Front Oncol. 2024. PMID: 39759134 Free PMC article.
-
Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia.Biomedicines. 2022 Nov 22;10(12):3008. doi: 10.3390/biomedicines10123008. Biomedicines. 2022. PMID: 36551764 Free PMC article. Review.
-
Targeting mutant fibroblast growth factor receptors in cancer.Trends Mol Med. 2011 May;17(5):283-92. doi: 10.1016/j.molmed.2011.01.012. Epub 2011 Mar 1. Trends Mol Med. 2011. PMID: 21367659 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous